Abstract
Background: Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined. Methods: We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3–5 CKD. Results: We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463–3.822; P = 0.0004], body mass index (OR 1.108; 95% CI 1.046–1.173; P = 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005–1.369; P = 0.0433), urinary albumin (OR 1.425; 95% CI 1.028–1.974; P = 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989–0.999; P = 0.0174). Conclusion: The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.
| Original language | English |
|---|---|
| Pages (from-to) | 1-14 |
| Number of pages | 14 |
| Journal | Clinical and Experimental Nephrology |
| DOIs | |
| Publication status | Accepted/In press - Jun 27 2018 |
Fingerprint
Keywords
- Albuminuria
- Antihypertensive agent
- Body mass index
- Chronic kidney disease
- Hypertension
- Left ventricular hypertrophy
- Mineral metabolism
ASJC Scopus subject areas
- Physiology
- Nephrology
- Physiology (medical)
Cite this
Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease : findings from the CKD-JAC study. / Nitta, Kosaku; Iimuro, Satoshi; Imai, Enyu; Matsuo, Seiichi; Makino, Hirofumi; Akizawa, Tadao; Watanabe, Tsuyoshi; Ohashi, Yasuo; Hishida, Akira.
In: Clinical and Experimental Nephrology, 27.06.2018, p. 1-14.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease
T2 - findings from the CKD-JAC study
AU - Nitta, Kosaku
AU - Iimuro, Satoshi
AU - Imai, Enyu
AU - Matsuo, Seiichi
AU - Makino, Hirofumi
AU - Akizawa, Tadao
AU - Watanabe, Tsuyoshi
AU - Ohashi, Yasuo
AU - Hishida, Akira
PY - 2018/6/27
Y1 - 2018/6/27
N2 - Background: Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined. Methods: We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3–5 CKD. Results: We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463–3.822; P = 0.0004], body mass index (OR 1.108; 95% CI 1.046–1.173; P = 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005–1.369; P = 0.0433), urinary albumin (OR 1.425; 95% CI 1.028–1.974; P = 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989–0.999; P = 0.0174). Conclusion: The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.
AB - Background: Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined. Methods: We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3–5 CKD. Results: We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463–3.822; P = 0.0004], body mass index (OR 1.108; 95% CI 1.046–1.173; P = 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005–1.369; P = 0.0433), urinary albumin (OR 1.425; 95% CI 1.028–1.974; P = 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989–0.999; P = 0.0174). Conclusion: The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.
KW - Albuminuria
KW - Antihypertensive agent
KW - Body mass index
KW - Chronic kidney disease
KW - Hypertension
KW - Left ventricular hypertrophy
KW - Mineral metabolism
UR - http://www.scopus.com/inward/record.url?scp=85049066785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049066785&partnerID=8YFLogxK
U2 - 10.1007/s10157-018-1605-z
DO - 10.1007/s10157-018-1605-z
M3 - Article
SP - 1
EP - 14
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
SN - 1342-1751
ER -